Communiqués eXoZymes, Inc.

Actions

EXOZ

US4618741098

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:30:00 29/09/2026			Varia. 5j.	Varia. 1 janv.
6,100 ^USD	+1,67%		-1,45%	-44,04%

11/09	Transcript : EXoZymes, Inc., Q2 2026 Earnings Call, Aug 20, 2026
13/08	EXoZymes, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Communiqués

08/09	EXoZymes Selects Curia as Commercial-Scale Manufacturing Partner for NCT	AQ
20/08	EXoZymes Reports Second Quarter 2026 Results and Provides Business Update at 5PM ET Today	AQ
18/08	EXoZymes' NCT Process Achieves 10-fold Productivity Increase, Advancing Beyond Original Commercial-scale Economic Targets	AQ
11/08	EXoZymes to Host Second Quarter 2026 Update Conference Call on Thursday, August 20, 2026	AQ
23/07	EXoZymes Selected for DoE's Genesis Mission to Advance AI-Powered Digital Twins for Cell-Free Biomanufacturing	AQ
24/06	EXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery	AQ
17/06	EXoZymes Inc. Announces Closing of $6 Million Public Offering	AQ
08/06	EXoZymes Inc. Announces Pricing of Public Offering of Common Stock and Warrants	AQ
07/05	EXoZymes Announces Graduation from Shell GameChanger(TM) Accelerator Powered by NLR (GCxN) Program	AQ
10/04	EXoZymes CCO, Damien Perriman, Outlines NCTx Strategy and the Commercial Path for Cell-Free Biomanufacturing on Grow Everything Podcast	AQ
31/03	EXoZymes Provides Fourth Quarter and Full Year 2025 Update	AQ
25/03	EXoZymes to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday March 31, 2026	AQ
18/03	Successful Pilot Scale Run with Cayman Chemical Validates eXoZymes' Technology and Scalability	AQ
12/03	EXoZymes' CCO Damien Perriman to Present a NCT Solution at Next Week's MISTA Symposium	AQ
05/02	Nasdaq: Michael B. Porter interviews CEO Heltzen	PU
30/01	EXoZymes : advancing commercial readiness with profound production metrics on initial NCT pilot run	PU
08/01	Beryl Elites: Interview with Capital Markets Advisor, Sanjeev Srivastava	PU
07/01	Beryl Elites: What is Artificial Evolution - an interview with CEO Heltzen	PU
18/12	International Business Times: AI meets enzymes - eXoZymes enables high-yield production of compounds previously impossible to make	PU
15/12	Beryl Elites: AI's Billion-dollar Bet on Life Sciences - From Drug Discovery to Patient Impact (panel)	PU
20/11	LA Weekly: The Enzyme Frontier: eXoZymes Unlocks a New Era for Cannabinoid Nutraceuticals and Pharma	PU
19/11	Slack Capital report: EXOZ is a once-in-a-lifetime opportunity	PU
18/11	'The Upside' interview: Michael Heltzen & Lou Basenese	PU
13/11	EXoZymes : Co-founder of eXoZymes and cell-free biomanufacturing pioneer, Tyler Korman, speaks to his new role as CSO	PU
11/11	Tyler Korman: How is eXoZymes uniquely positioned to take advantage of AI	PU